HomeCompareIMPL vs CL

IMPL vs CL: Dividend Comparison 2026

IMPL yields 5000.00% · CL yields 2.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IMPL wins by $62217131802825.31M in total portfolio value
10 years
IMPL
IMPL
● Live price
5000.00%
Share price
$0.04
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$62217131802825.35M
Annual income
$59,861,980,287,378,210,000.00
Full IMPL calculator →
CL
CL
● Live price
2.44%
Share price
$85.23
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41.0K
Annual income
$5,451.69
Full CL calculator →

Portfolio growth — IMPL vs CL

📍 IMPL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIMPLCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IMPL + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IMPL pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IMPL
Annual income on $10K today (after 15% tax)
$425,000.00/yr
After 10yr DRIP, annual income (after tax)
$50,882,683,244,271,480,000.00/yr
CL
Annual income on $10K today (after 15% tax)
$207.44/yr
After 10yr DRIP, annual income (after tax)
$4,633.94/yr
At 15% tax rate, IMPL beats the other by $50,882,683,244,271,470,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IMPL + CL for your $10,000?

IMPL: 50%CL: 50%
100% CL50/50100% IMPL
Portfolio after 10yr
$31108565901412.70M
Annual income
$29,930,990,143,689,110,000.00/yr
Blended yield
96.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

IMPL
Analyst Ratings
2
Buy
1
Hold
Consensus: Buy
Altman Z
-23.9
Piotroski
4/9
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+8.5% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IMPL buys
0
CL buys
0
No recent congressional trades found for IMPL or CL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIMPLCL
Forward yield5000.00%2.44%
Annual dividend / share$2.00$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28.6%
Portfolio after 10y$62217131802825.35M$41.0K
Annual income after 10y$59,861,980,287,378,210,000.00$5,451.69
Total dividends collected$62057786341622.61M$18.1K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold

Year-by-year: IMPL vs CL ($10,000, DRIP)

YearIMPL PortfolioIMPL Income/yrCL PortfolioCL Income/yrGap
1← crossover$510,700$500,000.00$11,014$313.84+$499.7KIMPL
2$24,410,935$23,864,485.98$12,200$415.44+$24.40MIMPL
3$1,092,192,501$1,066,072,800.30$13,607$553.09+$1092.18MIMPL
4$45,746,366,951$44,577,720,975.17$15,301$741.41+$45746.35MIMPL
5$1,793,932,828,410$1,744,984,215,772.56$17,374$1,002.00+$1793932.81MIMPL
6$65,871,973,805,320$63,952,465,678,921.49$19,958$1,367.44+$65871973.79MIMPL
7$2,265,146,887,602,700$2,194,663,875,631,007.20$23,243$1,887.87+$2265146887.58MIMPL
8$72,954,689,148,998,180$70,530,981,979,263,280.00$27,512$2,642.43+$72954689148.97MIMPL
9$2,201,076,182,660,884,700$2,123,014,665,271,456,500.00$33,197$3,759.22+$2201076182660.85MIMPL
10$62,217,131,802,825,350,000$59,861,980,287,378,210,000.00$40,973$5,451.69+$62217131802825.31MIMPL

IMPL vs CL: Complete Analysis 2026

IMPLStock

Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.

Full IMPL Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this IMPL vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IMPL vs SCHDIMPL vs JEPIIMPL vs OIMPL vs KOIMPL vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.